| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 10, 2012Late-Breaking Clinical Trial Validates Medtronic Proprietary Device Algorithms
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from the first and only clinical trial to show that Medtronic cardiac devices can safely...
-
May 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A...
-
May 8, 2012Implantable Medical Device for Endovascular Repair of Thoracic Aortic Aneurysms Also Being Studied for Minimally Invasive Treatment of Blunt Thoracic Aortic Injuries
MINNEAPOLIS--(BUSINESS WIRE)--May. 8, 2012-- Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant®...
-
Apr 30, 2012Medtronic Foundation has committed nearly $1.5 million in local scholarships.
MINNEAPOLIS--(BUSINESS WIRE)--Apr. 30, 2012-- The Medtronic Foundation today announced that 18 students have been selected as 2012 Medtronic Scholars. Each will receive a four-year scholarship...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...